<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00282620</url>
  </required_header>
  <id_info>
    <org_study_id>KLUG001817HE</org_study_id>
    <nct_id>NCT00282620</nct_id>
  </id_info>
  <brief_title>Magnesium to Reduce Implantable Cardioverter Defibrillator (ICD) Shocks and Improve Patient's Quality of Life.</brief_title>
  <official_title>The Adjuvant Magnesium Trial (AdMag): Assessment if the Impact of Oral Magnesium on ICD Firing and Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hartford Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hartford Hospital</source>
  <brief_summary>
    <textblock>
      This study is being conducted to see if magnesium can reduce the number of shocks patients
      with ICDs experience and to see if magnesium supplementation improves patients quality of
      life.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Not all ICD shocks are for ventricular arrhythmias. Some patients receive shocks when they
      have arrhythmias in the atria (top chambers of the heart). These are called inapproriate
      shocks, but the pain is similar to the pain patients feel with an appropriate shock (a shock
      for a ventricular arrhythmia). This study is being conducted to determine if taking magnesium
      can reduce the number of shocks patients with ICDs experience and to see if magnesium
      supplementation improves patients quality of life. Magnesium's impact of the
      electrocardiogram (ECG) and intracellular magnesium concentrations will also be studied.

      Comparison: Magnesium compared to placebo in patients with ICDs to evaluate the number of ICD
      shocks and patient perceived quality of life.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2006</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cumulative occurrence of ICD shocks and patient perceived quality of life at baseline, 3,6,9, and 12 months</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in QTc interval in the total population and the subgroup receiving class III antiarrhythmics at baseline, 3, 6, 9, 12 months.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intracellular magnesium concentrations at baseline, 3 and 12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of supraventricular arrhythmias, ventricular arrhythmias, and sinus tachycardias at baseline, 3,6,9,12 months.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventricular fibrillation cycle length and the variability in VFCL at baseline, 3,6,9,12 months</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events at basline, 3,6,9,12 months. Total Hospital Costs and Cost-effectiveness.</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Arrhythmia</condition>
  <condition>Quality of Life</condition>
  <condition>Hypomagnesemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium L-lactate</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:newly implanted ICD or recent ICD shock (within 6 months) -

        Exclusion Criteria:inability to swallow, a non-cardiac disease with a survival prognosis of
        less than 12 months, hypermagnesemia, a creatinine clearance less than 30mL/min, lactic
        acidosis or systemic acidosis syndrome, or previous intolerance to magnesium L-lactate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jeffrey Kluger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hartford Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jeffrey Kluger, MD</last_name>
    <phone>860-545-2883</phone>
    <email>Jkluger@harthosp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Charles M White, PharmD</last_name>
    <phone>860-545-2221</phone>
    <email>Cmwhite@harthosp.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hartford Hospital</name>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06102-5037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jeffrey Kluger, MD</last_name>
      <phone>860-545-2883</phone>
      <email>JKluger@harthosp.org</email>
    </contact>
    <contact_backup>
      <last_name>Charles M White, PharmD</last_name>
      <phone>860-545-2221</phone>
      <email>Cmwhite@harthosp.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Kluger, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charles M White, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nickole N Henyan, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephen D Sander, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Craig I Coleman, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Effie L Gillespie, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christopher A Clyne, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William L Baker, PharmD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2006</study_first_submitted>
  <study_first_submitted_qc>January 25, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2006</study_first_posted>
  <last_update_submitted>November 16, 2007</last_update_submitted>
  <last_update_submitted_qc>November 16, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 20, 2007</last_update_posted>
  <keyword>Implantable Cardioverter Defibrillator</keyword>
  <keyword>Magnesium</keyword>
  <keyword>Electrocardiogram</keyword>
  <keyword>Ventricular Arrhythmia</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

